Search Results for “Novo Nordisk ” – Page 15 – media

FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 595
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
Drug can dramatically reduce weight of people with obesity

A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
- Source: Sciencedaily
- 658
- October 27, 2017
obesity semaglutide weight loss
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 32
- November 22, 2024
CIIE Observation | Eli Lilly’s Two “Focuses”

Today, the seventh CIIE opened grandly in Shanghai. Every year, the CIIE is an excellent opportunity for global pharmaceutical companies to showcase their latest research and development results and expand international markets, and it is also a core window for insight into Chinese market opportunities. This year will be no exception. So, let’s take a look at Eli Lilly, a pharmaceutical company with nearly 150 years of history, and its latest thinking. As an all-around warrior, this year Eli Lilly focused on displaying its latest progress in key global disease areas such as diabetes, obesity, Alzheimer’s disease and anti-tumor. In the big and comprehensive layout, Eli Lilly also revealed its two major focuses of development in China: diabetes and obesity, and Alzheimer’s disease. At this CIIE, Eli Lilly focused on displaying tirpotide. This is not surprising. As Eli Lilly’s flagship product, tirpotide is one of the most competitive GLP-1 drugs ...
- Source: drugdu
- 60
- November 7, 2024
The second day of the 2024 National Negotiations | Hengrui, CSPC Pharmaceutical, Qilu Pharmaceutical, AstraZeneca…appeared! Antidiabetic and tumor drugs may be the focus

The 2024 National Medical Insurance Negotiations entered the second day. Beijing was sunny. On this day, antidiabetic and tumor drugs were the highlights. On the second day of the National Negotiations, Huang Bin, Vice President of AstraZeneca China, and Xia Yu, founder, chairman, president and CEO of Kangfang Bio, appeared at the National Negotiations. On the morning of October 28, the companies participating in the negotiations included AstraZeneca, Hengrui, Xinlitai, Hisun, CSPC Pharmaceutical, etc.; in the afternoon, Zhejiang Jingxin Pharmaceutical, Union Qilin, Beijing Novartis, Luye Pharmaceutical, Jiangsu Hausen, Bristol-Myers Squibb, Qilu, Changchun Jinsai, Zejing Bio, Hengrui, Novo Nordisk, etc. were present. Some on-site observers said that anti-tumor, antidiabetic and other chronic disease drugs were the protagonists of the second day of the National Negotiations. The National Medical Insurance Administration has carried out adjustments to the medical insurance drug list for six consecutive years, adding a total of 744 drugs to ...
- Source: drugdu
- 57
- October 30, 2024
GLP-1 Can Improve Opioid Addiction Issues

A recent study indicates that Novo Nordisk’s Ozempic and similar GLP-1 medications may reduce patients’ misuse of opioids and alcohol, further demonstrating the broad potential of GLP-1 drugs beyond treating obesity and diabetes. This study was published on Thursday, October 17, in the journal *Addiction*. The research aims to further explore the growing potential uses of GLP-1 and seeks to address the troubling issue of opioid addiction among patients. An analysis conducted on 500,000 opioid-addicted patients revealed that those using GLP-1 medications had a 40% lower rate of opioid overdose compared to those who did not take GLP-1 medications. Additionally, similar comparative research was conducted among alcoholics. The results showed that among over 5,000 alcoholics using GLP-1 drugs, the rate of excessive drinking was 50% lower compared to those not using GLP-1. New Treatment Options The lead researcher, Dr. Fares Qeadan, an associate professor of biostatistics at Loyola University Chicago, ...
- Source: drugdu
- 70
- October 18, 2024
After the 2024 Nobel Prize is announced, what is the commercial value?

The 2024 Nobel Prize in Physiology or Medicine has finally been announced, and surprisingly, the previously highly requested GLP-1 target and alphafold system have not been awarded, and the award-winning fields are similar to last year, which are pioneers in the field of RNA. Last year it was mRNA, this year it is microRNA. On October 7 at 5:30 p.m., the Sweden Carolinska Institutet announced that the 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun · · for their “discovery of microRNAs and their role in post-transcriptional gene regulation.” It is reported that the two are professors at the University of Massachusetts Medical School and Harvard Medical School, respectively. As we all know, the winner of the Nobel Prize needs to go through a long time from making relevant achievements to winning the Nobel Prize: the Nobel Prize needs time to test its ...
- Source: drugdu
- 86
- October 15, 2024
From the rise of Sinocell, we can see the first principles of pharmaceutical companies

In the 1950s, George W. Merck, then CEO of Merck, said a widely circulated saying in the pharmaceutical industry: “We should always remember that drugs are produced for humans, not for the pursuit of profits. As long as we stick to this belief, profits will follow.” It is true. Looking at large overseas pharmaceutical companies, the key to their success lies in patient-centeredness and a strong sense of social responsibility. In China, there are more and more such examples. For example, the vision of Sinocell is to focus on the research and development of drugs urgently needed by the people and provide patients with high-quality and affordable biological drugs. It seems to coincide with Merck. On the product side, Sinocell uses technological innovation to provide higher quality and lower cost drugs, which reduces the economic burden of domestic patients, while bringing better treatment effects and achieving a win-win situation of ...
- Source: drugdu
- 80
- September 30, 2024
CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come. By Frank VinluanMedicare has unveiled prices for the first 10 drugs selected for its negotiation program, resulting in discounts of as much as 79% off of list prices. Taxpayers will save an estimated $6 billion, the White House said in a Thursday announcement of the new prices. The savings won’t happen right away. New pricing for these products won’t take effect until Jan. 1, 2026 for those with Medicare Part D prescription drug coverage. But these 10 widely used products in therapeutic areas such as diabetes and autoimmune disorders represent the first of many drugs on a path to ...
- Source: drugdu
- 106
- August 19, 2024
Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug

Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year. By Frank VinluanRoche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that keep the pharmaceutical giant in contention to bring patients a pill to tap into this increasingly popular mechanism for weight loss. The results reported Wednesday are from a Phase 1 test of CT-996, a once-daily pill designed to activate the GLP-1 receptor to treat type 2 diabetes and obesity. Roche said treatment of patients who are obese and do not have type 2 diabetes lost a placebo-adjusted average of 6.1% of body weight within ...
- Source: drugdu
- 97
- July 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.